Introduction
Protein Homeostasis Therapies is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
flowchart TD
Protein_Homeostasis_Therapies["Protein Homeostasis Therapies"] -->|"references"| HTT["HTT"]
Protein_Homeostasis_Therapies["Protein Homeostasis Therapies"] -->|"references"| BACE1["BACE1"]
Protein_Homeostasis_Therapies["Protein Homeostasis Therapies"] -->|"references"| TFEB["TFEB"]
style Protein_Homeostasis_Therapies fill:#4fc3f7,stroke:#333,color:#000
Protein homeostasis (proteostasis) is essential for neuronal health. Neurodegenerative diseases are characterized by accumulation of misfolded proteins—[amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) in Alzheimer's disease, [alpha-synuclein](/mechanisms/alpha-synuclein) in Parkinson's disease, mutant [huntingtin](/proteins/huntingtin-protein) in Huntington's disease, and [TDP-43](/proteins/tdp-43) in ALS. Therapies targeting the proteostasis network aim to restore proper protein folding, clearance, and turnover.
The proteostasis network comprises molecular chaperones, the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system) (UPS), and the autophagy-lysosomal pathway (ALP). These interconnected systems work together to maintain cellular protein quality control, and their dysfunction is a hallmark of neurodegenerative diseases["@butler2022"].
Proteostasis Network
The Three Pillars
...Introduction
Protein Homeostasis Therapies is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Protein homeostasis (proteostasis) is essential for neuronal health. Neurodegenerative diseases are characterized by accumulation of misfolded proteins—[amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) in Alzheimer's disease, [alpha-synuclein](/mechanisms/alpha-synuclein) in Parkinson's disease, mutant [huntingtin](/proteins/huntingtin-protein) in Huntington's disease, and [TDP-43](/proteins/tdp-43) in ALS. Therapies targeting the proteostasis network aim to restore proper protein folding, clearance, and turnover.
The proteostasis network comprises molecular chaperones, the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system) (UPS), and the autophagy-lysosomal pathway (ALP). These interconnected systems work together to maintain cellular protein quality control, and their dysfunction is a hallmark of neurodegenerative diseases["@butler2022"].
Proteostasis Network
The Three Pillars
1. Molecular Chaperones:
- [Heat shock proteins](/entities/heat-shock-proteins) (HSP70, HSP90, HSP40)
- Chaperonins (TRiC/CCT)
- Small heat shock proteins (αB-crystallin/HSPB5)
- Co-chaperones (HOP, CHIP, BAG family)
2. [Ubiquitin-Proteasome System](/cell-types/ubiquitin-proteasome-system) (UPS):
- E1 ubiquitin-activating enzymes
- E2 ubiquitin-conjugating enzymes
- E3 ubiquitin ligases (>600 human E3s)
- 26S proteasome (19S regulatory particle, 20S core)
- Deubiquitinating enzymes (DUBs)
3. [Autophagy](/entities/autophagy) Pathway:
- Macroautophagy (bulk degradation)
- Chaperone-mediated autophagy (CMA) - LAMP2A-dependent
- Microautophagy
- Endosomal microautophagy
Therapeutic Approaches
HSP90 Inhibitors
Heat shock protein 90 (HSP90) is a molecular chaperone that stabilizes many client proteins, including pathogenic kinases and mutant proteins. Inhibiting HSP90 can promote the degradation of disease-causing proteins through the proteasome[@luo2020].
Mechanism: Inhibition releases pre-bound client proteins for degradation via the proteasome or autophagy
Drugs in Development:
- Tanespimycin (17-AAG): First-generation HSP90 inhibitor, completed Phase I in ALS
- Geldanamycin derivatives: Early prototypes
- NVP-HSP990: Second-generation inhibitor with better oral bioavailability
- AT13387: Long-acting HSP90 inhibitor
- PU-H71: Tumor-specific HSP90 inhibitor
Clinical Status: Phase I/II trials in ALS, Alzheimer's, and pancreatic cancer
HSP70 Inducers
HSP70 family proteins are key guardians of protein folding that can prevent aggregation and facilitate refolding[@koyama2021].
Mechanism: Upregulate protective chaperone expression via HSF1 activation
Agents:
- Geranylgeranylacetone (GGA): Approved in Japan for gastric ulcers, HSP70 inducer
- Arimoclomol: HSP90/HSP70 co-inducer, Phase III in ALS
- 17-DMAG (Alvespimycin): HSP90 inhibitor with better solubility
- Natural compounds: Withaferin A, celastrol
Clinical Status: Arimoclomol in Phase III for ALS (FOURIER trial)
Proteasome Modulators
The ubiquitin-proteasome system handles the degradation of most cellular proteins. Modulating this system can enhance clearance of misfolded proteins[@song2023].
Approaches:
- E3 ligase modulators: Enhance ubiquitination of disease proteins
- Proteasome activators: 11S REG subunits enhance proteasome activity
- Deubiquitinase inhibitors: Prevent removal of ubiquitin chains needed for degradation
Challenges:
- Global proteasome inhibition is toxic
- Need for tissue-specific targeting
Autophagy Inducers
Autophagy removes large protein aggregates and damaged organelles that cannot be handled by the proteasome.
[mTOR](/entities/mtor) Inhibitors:
- Rapamycin (Sirolimus): Classic autophagy inducer, FDA approved for transplant
- Rapalogs (rapamycin analogs): Temsirolimus, Everolimus
- Limitations: Immunosuppression, metabolic effects
AMPK Activators:
- Metformin: FDA-approved diabetes drug, AMPK activator
- AICAR: AMPK synthetic activator
- Natural compounds: Resveratrol, curcumin, spermidine
[TFEB](/entities/tfeb) Activators:
- Gene therapy approaches: AAV-TFEB delivery
- Small molecule TFEB activators: Natural products and synthetic compounds
- Lithium: Known TFEB activator
Protein Aggregation Inhibitors
Direct inhibition of protein aggregation represents another therapeutic strategy.
Approaches:
- β-sheet breaker peptides: Designed to prevent fibril formation
- Small molecule inhibitors: Bind to aggregation intermediates
- Antibody-based approaches: Anti-oligomer antibodies
Examples:
- Anle253b: [Tau](/proteins/tau) aggregation inhibitor
- PRX-003: [α-synuclein](/proteins/alpha-synuclein) aggregation inhibitor
Disease-Specific Targeting
Alzheimer's Disease
- HSP90 inhibitors: Client proteins include tau, [BACE1](/entities/bace1), and AβPP
- Autophagy enhancers: Clear [Aβ](/proteins/amyloid-beta) and tau aggregates
- UPS modulators: Enhance tau degradation
- Combination approaches: Target multiple pathways simultaneously
Parkinson's Disease
- Autophagy inducers: Clear α-synuclein aggregates
- HSP70 inducers: Reduce α-synuclein toxicity
- CMA modulators: Enhance LAMP2A function for α-synuclein clearance
- GCase modulators: Target glucocerebrosidase for α-synuclein
Huntington's Disease
- HSP90 inhibitors: Promote mutant [HTT](/genes/htt) clearance
- Autophagy enhancers: Clear protein aggregates
- UPS modulators: Enhance HTT degradation
- Allele-selective approaches: Target mutant protein specifically
ALS
- Autophagy inducers: Clear [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates
- HSP70/HSP90 modulators: Protect SOD1, FUS
- Protein aggregation inhibitors: Multiple targets in development
- [Unfolded protein response](/entities/unfolded-protein-response): Target ER stress
Clinical Trials
| Agent | Target | Disease | Phase | Status |
|-------|--------|---------|-------|--------|
| Arimoclomol | HSP co-inducer | ALS | III | Ongoing |
| Tanespimycin | HSP90 | ALS | I/II | Completed |
| Rapamycin | [mTOR](/proteins/mtor-protein) | Alzheimer's | II | Completed |
| Metformin | AMPK | Alzheimer's | II/III | Ongoing |
| Lithium | Various | ALS/AD | II | Mixed results |
Combination Strategies
Rationale for combining proteostasis-targeted therapies:
| Combination | Rationale |
|-------------|-----------|
| HSP90i + Autophagy | Sequential targeting - release aggregates then clear them |
| Proteasome + Autophagy | Parallel clearance via different pathways |
| Chaperone + Degraders | Full proteostasis network activation |
| Autophagy + Anti-aggregation | Prevent aggregate formation AND enhance clearance |
Biomarkers for Treatment Response
Monitoring proteostasis modulation requires specific biomarkers:
- HSP70 levels: Peripheral blood mononuclear cell measurements
- Proteasome activity: 20S proteasome assays in blood/CSF
- Autophagy markers: LC3 turnover, p62 degradation, beclin-1
- Aggregate clearance: CSF tau, α-synuclein, HTT fragments
- Ubiquitinated proteins: Total ubiquitin levels
Advantages and Challenges
Advantages:
- Addresses root cause of protein aggregation
- Potential for disease modification
- Applicable across multiple proteinopathies
- May work synergistically with other approaches
Challenges:
- Balancing protein turnover (degradation vs. refolding)
- Off-target effects from global pathway modulation
- CNS delivery of therapeutic agents
- Need for patient selection based on proteostasis status
See Also
- [Protein Quality Control Network](/mechanisms/protein-quality-control-network)
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade)
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
- [Autophagy Inducers](/therapeutics/autophagy-inducers-neurodegeneration)
- [HSP90 Inhibitors](/therapeutics/hsp90-inhibitors-neurodegeneration)
External Links
- [Alzheimer's Association: Research](https://www.alz.org/)
- [ALS Association: Research](https://www.als.org/)
- [PubMed: Proteostasis](https://pubmed.ncbi.nlm.nih.gov/)
- [ClinicalTrials.gov: Proteostasis modulators](https://clinicaltrials.gov)
Background
The study of Protein Homeostasis Therapies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Butler D, et al, (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35654976/)
Luo W, et al, (2020) (2020)
Koyama S, et al, (2021) (2021)
Song JX, et al, (2023) (2023)
Hipp MS, et al, (2019) (2019)